Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney  by Barthelmebs, Mariette et al.
Kidney International, Vol. 37 (1990), pp. 1414—1422
Metabolism and vascular effects of gamma-L-glutamyl-L-dopa
on the isolated rat kidney
MARIETTE BARTHELMEBS, AGNES CAILLETTE', JEAN-DANIEL EHRHARDT, JEANNE VELLY, and
JEAN-LOUIS IMBS
Institut de Pharmacologie, Faculté de Medecine and URA D0589 CNRS, Université Louis Pasteur, Strasbourg, France
Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the
isolated rat kidney. Gamma-L-glutamyl-L-dopa (or gludopa), a dopam-
me (DA) prodrug, is selectively metabolized in vivo by the kidney
through the sequential action of two renal enzymes, gamma-glutamyl
transpeptidase (gamma-GT) and aromatic L-amino acid decarboxylase
(AADC). This study was designed to analyze, in vitro, the factors
regulating gludopa metabolism and its renal vascular effects. Rat
kidneys were perfused in closed circuit with a cell-free perfusion buffer
containing 6% bovine serum albumin (BSA). Adding gludopa (final
concentration l0 M in the perfusate) led to the release of DA both into
urine and perfusate (0.53 0.21 and 1.38 0.28 nmol/min/g kidney wt,
respectively, during the first S mm after substrate addition, N = 5, mean
sEM). Total DA release (urine plus perfusate) was 73.7 15.8 nmol/g
kidney wt within 30 minutes of recirculation. In non-filtering kidneys,
total DA release in the recirculating medium was lower (12.5 1.4
nmollg kidney wt, P < 0.01). Glomerular filtration and access to the
gamma-GT on the brush border membrane of proximal tubular cells are
therefore required for the maximal conversion rate of gludopa. On
filtering kidneys, L-dopa was also converted to DA, but at a higher rate
than gludopa (total DA formed within 30 mm of recirculation = 131.2
31.9 nmollg kidney wt) and this rate was not reduced in non-filtering
kidneys (224.2 41.7 nmollg kidney wt DA formed within 30 mm).
Metabolic conversion of L-dopa by AADC is thus preserved in the case
of an approach via the basolateral side of the proximal tubular cells. The
renal vascular effects of gludopa were studied after vascular tone had
been restored by continuous perfusion of PGF2, and after the inhibition
of alpha- and beta-adrenoceptors. Gludopa (3.10—6 to 4. iO M) elicited
concentration-dependent renal vasodilatation. At 4. l0- M, the renal
response was similar to that elicited by DA and L-dopa at concentra-
tions respectively 20 and 2 times lower. These responses were abol-
ished by a DA-l receptor antagonist, SCH 23390. Inhibition of gamma-
GT by AT-125 (10_6 M) reduced gludopa-induced renal vasodilatation,
as did carbidopa (10k M), on the L-dopa-induced renal response.
Gludopa- and L-dopa-induced renal vasodilatations are directly linked
to endorenal release of DA which interacts with vascular DA- I recep-
tors.
The renal vasodilator effect of dopamine (DA) predominates
on the efferent glomerular arteriole [1, 2]. It can reduce intra-
glomerular pressure and might have therapeutic applications in
treating arterial hypertension. This use, however, runs up
against the poor bio-availability of the catecholamine and the
lack of specificity of its pharmacological effects; for doses only
two or three times higher than those which elicit effects due to
the stimulation of dopamine receptors (increase in renal blood
flow, reduction in the filtration fraction, increase in natriuresis),
an increase in heart rate and peripheral vasoconstriction occur,
due to the stimulation of alpha- and beta-adrenoceptors. Thus,
when DA has been used clinically, cases of gangrene [3, 4],
hypertensive bursts and cardiac arythmias [5] have been re-
ported.
The development of prodrugs giving rise to the endorenal
release of DA is one way of alleviating these drawbacks. The
abundance in the kidney of gamma-glutamyl transpeptidase
(gamma-GT, EC. 2.3.2.2.) has been exploited to this end [6].
Thus, gamma-L-glutamyl-L-dopa or gludopa [7, 8] has led, in
vivo, to an accumulation of DA confined to the renal paren-
chyma. It reproduces the renal effects of DA in the animal [9]
and in man [10] but without any major systemic effects.
Gamma-L-glutamyl dopamine, described by Kynci et al [11]
proved less selective and active on the kidney [81; the superi-
ority of gludopa is probably related to a greater affinity for
gamma-GT [12] and/or to the involvement of a second enzyme,
the aromatic L-amino acid decarboxylase (AADC, EC
4.1.1.2.8.). The activity of this enzyme is particularly high in the
kidney [13], where it is present with gamma-GT at the proximal
tubular level [14, 15].
This study was designed to analyze, in vitro, on the isolated
perfused rat kidney, the renal metabolism of gludopa. Its renal
vasodilator response was also characterized and compared to
that of L-dopa. Our results show that it is the endorenal
synthesis of DA and the stimulation of DA- 1 receptors which
explain gludopa (and L-dopa)-induced renal vasodilatation.
Methods
Isolated rat kidney preparation
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Male Wistar rats (170 to 220 g) were purchased from SEXAL
(Montmedy, France). They had free access to tap water and a
standard diet until they were anaesthetized with sodium pento-
barbital (45 mg/kg, i.p.). The right kidney was prepared without
ischemia and set on perfusion via the mesentenc artery, as
previously described [16]. The isolated kidney was perfused in
closed circuit with 50 ml of Krebs-Henseleit bicarbonate buffer
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supplemented with bovine serum albumin (BSA) as an oncotic
agent. A BSA stock solution (75 g/liter Krebs-Henseleit bicar-
bonate buffer) was dialyzed overnight against 10 volumes of the
same buffer and made up to the following final composition:
Na 145; K 5.1; Ca 1.1; Mg 0.6; C1 114.3; H2P04 1.2;
HC03 25; urea 6; glucose 5; oxaloacetic acid 1; glutamic acid
5; lactic acid 5; pyruvic acid 2; L-methionine 0.5; L-alanine 2;
glycine 2; L-serine 2; L-proline 2; L-isoleucine 1 and L-aspartic
acid 3 (in i0 M); inulin 0.5 glliter; BSA 60 g/liter. This solution
was frozen in aliquots of 80 ml and used after sterile filtration
(0.22 pm filter, Millipore, Saint Quentin, France). The perfusate
was equilibrated with 95% 02 and 5% CO2 to obtain a physio-
logical pH (7.4 0.05, N = 51, mean SEM) and 02, CO2
partial pressures of respectively 401 13 and 45 1 mm Hg
(Blood gas analyzer, 178 PH, Corning, Iialstead, UK). After an
initial recovery period, the perfusion pressure (Statham P23 Db)
was adjusted to about 100 mm Hg, the perfusion rate was then
kept constant throughout the experiment. Diuresis was mea-
sured by gravimetry, and the sodium concentrations by flame
photometry (IL 343, Instrumentation Laboratory, Lexington,
Massachusetts, USA). The functional state of the isolated
perfused kidneys (IPK) was determined between 15 and 30
minutes after perfusion began. The glomerular filtration rate
was assessed from inulin clearance, and fractional tubular
sodium reabsorption was calculated with the usual formulae.
Since the perfused kidney developed a slight edema (18% gain
in weight), the weight of the controlateral non-perfused kidney
was used for expressing results on a gram basis.
To analyze the contribution of peritubular access to the
enzymes in the metabolism of gludopa, studies were also
performed on non-filtering kidneys. Glomerular filtration was
abolished by raising the oncotic pressure of the perfusate (BSA
100 g/liter) and lowering perfusion pressure to 70 mm Hg
according to Maack [17]. The ureter was also ligated.
The perfusate consistently contained 10 M of sotalol and
lO M of phenoxybenzamine to block the alpha- and beta-
adrenoceptors. At this high concentration, phenoxybenzamine
also blocked neuronal and extraneuronal uptake mechanisms
[18, 19] and therefore might also block DA metabolism by
COMT and MAO.
Metabolism studies
Mter a five minute control period, gludopa was injected, at
the 35th minute of perfusion, directly into the recirculation
reservoir (final concentration 10 M). Urine and perfusate
aliquots (200 d) were sampled respectively via the ureter and
the renal venous catheter, every 5 or 10 minutes, for measure-
ment of DA content. Samples were collected in iced tubes
containing 10 mg Na2S2O5 as antioxydant. They were stored at
— 18°C until analysis by gas chromatography-mass spectrome-
try, as described previously [20]. The presence of conjugate DA
or of gamma-L-glutamyl dopamine was investigated after acid
hydrolysis of the samples (HC1 N at 90°C for 30 mm). Gludopa
(l0— M final concentration) was also injected into the perfusate
of non-filtering kidneys, and perfusate sampling was done as
described above.
The renal metabolism of gludopa was compared to that of
L-dopa (l0 M final concentration) on both filtering and
non-filtering kidneys, according to the same protocols.
In situ enzyme activities on the perfused kidney were evalu-
ated by calculating the rate of DA appearance (nmollmin/g of
kidney wt) or the cumulative amounts of DA released into the
perfusate or in the urine (nmoL/g of kidney wt). The rate of
substrate delivered to the whole kidney, to the luminal side and
to the antiluminal side were calculated as: substrate concentra-
tion in the perfusate x renal flow, substrate concentration in the
perfusate x glomerular filtration rate and substrate concentra-
tion in the perfusate x (renal flow-glomerular filtration rate).
Pharmacodynamic studies
The renal vascular response induced by gludopa (3 x 10_6 to
4 X 10 M, final cumulative concentration) was studied on
filtering kidneys under the experimental conditions [21] which
had previously enabled us to reveal DA-l receptor-related
vasodilatation: presence of phenoxybenzamine and sotalol at
l0 M and re-establishment of a vascular tone by the contin-
uous perfusion of prostaglandin F2 (PGF2a, 1.3 0.15 x i0
mollmin) which increased the perfusion pressure by 25 1.1%
(N = 38). The vasodilator effects of gludopa were compared
with those of DA (3 x 107to 1.4 X 104M)orofL-dopa(106
to 4.4 x l0— M). These responses were checked for their
specific inhibition by a selective DA-l receptor antagonist, SCH
23390 [22]. This antagonist was perfused continuously (6 xl0 1 mol/min) to give a final concentration of approximately 3
x iO M in the perfusate. Gludopa, L-dopa and DA were
tested after 15 minutes of contact with the antagonist. A single
concentration-response curve was done on each kidney prepa-
ration.
The role of the endorenal synthesis of DA was studied for
gludopa in the presence of AT-l25 (106 M), a gamma-GT
inhibitor [23], and, for L-dopa in the presence of carbidopa, an
AADC inhibitor [24]. Carbidopa was injected into the rats (5
mg/kg, i.p.) 30 minutes before kidney perfusion began and then
was added to the perfusate (10—a M) 15 minutes before testing
L-dopa. The inhibition of endorenal DA synthesis was checked
by verifying the DA concentration in the perfusate at a time
when the residual vascular response was maximum.
The vasodilator response to papaverine (10 M) was tested
at the end of each experiment. It was, on average, equal to a 102
4.7% reversion of the constriction induced by PGF2 (N
38). Relaxations induced by other drugs are expressed as a
percentage of papaverine-induced response.
Drugs
The following drugs were used: gamma-L-glutamyl-L-dopa
or gludopa (UCB Bioproduct, Paris, France), dopamine and
L-dopa hydrochloride (Fluka, Buchs, Switzerland), papaverine
hydrochloride (Sigma, St Louis, Missouri, USA), SCH 23390
(Schering, Bloomfield, Illinois, USA), AT-125 or acivicin (Dr.
Suffness, NCR, Bethesda, Maryland, USA); carbidopa (Merck
Sharp and Dohme Research Labs, Rahway, New Jersey, USA),
phenoxybenzamine hydrochloride (Röhm Pharma, Darmstadt,
FRG), (±)-sotalol hydrochloride (Laboratoire Bristol-Allard,
Paris, France), prostaglandin F2a thromethamine salt (Upjohn
Company, Kalamazzo, Michigan, USA), bovine serum albu-
min, fraction V (Sigma), aminoacids (Merck, Darmstadt, FRG).
Other drugs were as specified previously [16, 201.
Gludopa, dopamine and L-dopa were dissolved in 0.28 M
glucose, SCH 23390 (l0 M) was set up in 40% absolute
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ethanol in water (vollvol) and diluted further with 0.15 M NaC1.
The solvent, per Se, did not affect the renal perfusion pressure.
Statistics
Results are expressed as means SEM. Statistical signifi-
cance was determined with Student's t-test or variance analysis
followed by Scheffe's test [251. P values  0.05 were considered
non-significant.
Results
Functional characteristics of isolated perfused rat kidneys
The following parameters were measured on 52 isolated
filtering kidney preparations, fifteen minutes after setting them
on perfusion: perfusion pressure 104 0.8 mm Hg; renal flow
28 0.9 mllmin/g kidney wt; glomerular filtration rate 0.77
0.04 ml/minlg kidney wt; diuresis 49 4 pi/min/g kidney wt;
fractional tubular sodium reabsorption 96 0.8%. In non-
ifitering kidneys (N = 10), perfusion pressure was adjusted to 70
1 mm Hg for a mean perfusion rate of 14 1.2 ml/min/g
kidney wt.
Basal DA release by the isolated kidneys was checked on two
preparations. During a 45 minute perfusion, the urinary DA
flow was 0.02 x i0 mollminlg at the most and no DA was
detected in the renal venous effluent of the kidney.
Gludopa and L-dopa metabolism
After the injection of gludopa into the perfusate (final con-
centration 10 M), DA was rapidly synthesized by the kidney,
as is witnessed to by the appearance of the catecholamine in the
urine and in the perfusate within the first minutes (Fig. 1). The
urinary DA excretion rate reached a maximum within 10
minutes after gludopa injection (basal excretion = 0.02 0.01
X iO mollmin/g kidney wt; maximum excretion = 1.63 0.53
x lO mol/min/g kidney wt) and then decreased progressively.
Cumulative urinary DA excretion (Fig. 1) continuously in-
creased up to the 50th minute of recirculation. DA also ap-
peared in the renal venous effluent. DA release into the renal
venous effluent, considered as a release from the basolateral
side of proximal tubular cells, was higher, in the first five
minutes following gludopa administration, than DA release into
the urine, considered as a release from the luminal side (Table
1). Gludopa was nevertheless metabolized with a greater yield
from the luminal side since 5.47% of the substrate delivered to
the luminal side was metabolized to DA compared to only
0.46% on the basolateral side; DA in the urine represented up to
27.7% of the total DA released by the kidney during the initial
five minutes and up to 41.1% for the initial 10 minutes (Table 1).
The DA partition between the urinary and vascular compart-
ments evolved with the time of recirculation, so that the amount
of DA in the urine became equal to the amount of DA in the
perfusate at the end of the experiment (Fig. 1). Cumulative DA
amounts in the perfusate reached maximum within 30 minutes
of gludopa injection (Fig. 1) giving a perfusate DA concentra-
tion of 0.69 0.13 x 10—6 M.
The injection of L-dopa (final concentration i0 M) also led
to endorenal DA synthesis and the release of DA into the urine
and the perfusate (Fig. 2). The DA release induced by L-dopa
was greater than that induced by gludopa despite similar
amounts of substrate being delivered to the luminal or basolat-
Time, minutes
Fig. 1. The cumulative DA release, on filtering kidneys, into the
perfusate (•), the urine (A), or the sum of both (U) and, on non-filtering
kidneys, the DA release into the perfusate (l) after addition of gludopa
to the perfusate. Gludopa was injected at the 35th mm of perfusion to
give an initial concentrStion of 10 M in the perfusate. Aliquots of the
renal venous effluent were sampled every 5 or 10 mm. Urine was
collected over the same periods. Statistical significance refers to the
comparison of cumulative total DA release on filtering and non-filtering
kidneys. *p < 0.05; < 0.01; *** < 0.001. Means SEM; N = 5.
eral sides of the kidney (Tables 1 and 2). Indeed, the maximum
urinary DA excretion rate at the tenth minute alter L-dopa
injection was increased (3.9 1.1 x l0 mol/minig kidney wt,
P < 0.05 versus gludopa, one-tailed Student's t-test), as were
the cumulative urinary DA excretion within 30 minutes of
L-dopa recirculation (70 16 vs. 34 9 x i0 mollg kidney wt
after gludopa, P <0.05), the mean rates for DA release into the
perfusate during the first five or ten minutes after substrate
administration (Table 1), the mean rate of total DA release
(perfusate and urine) during the first five minutes (Table 2) and
the maximum DA concentration in the perfusate (1.05 0.27 x
10—6 M). Moreover, the DA partition between the urinary and
the vascular compartment differed from that observed with
gludopa in the initial five or ten minutes. Here, urinary DA
excretion represented only 14 or 25% of the total DA release by
the kidney (Table 1).
Whether the precursor was gludopa or L-dopa, the renal
clearance of DA was always high (2 to 6 mllmin/g) (Fig. 3).
During the 30 minutes following the injection of the precursors,
it was significantly higher than the glomerular filtration rate
measured on the same preparations just before the injection of
gludopa or of L-dopa (0.99 0.13 and 0.81 0.12 mllminlg)
(Student's paired t-test, P < 0.001). Renal DA clearance was
not significantly different after the injection of gludopa or of
L-dopa.
The DA formed by the isolated kidneys and excreted in the
urine or present in the perfusate was always in its free form; no
conjugated dopamine was found whatever the precursor used.
Metabolism on non-filtering kidneys
We checked the absence of glomerular filtration on these
isolated kidney preparations. The inulin concentration in the
100
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Table 1. Luminal and antiluminal rates of DA synthesis by the isolated perfused rat kidney, during the first 5 or 10 minutes of recirculation
after substrate addition to the perfusate
Substrate
Filtering kidneys Non-filtering kidneys
Gludopa L-dopaGludopa L-dopa
Renal flow mi/minlg 30.7 2.8 32.2 1.9 16.8 1.9 13.4 1.6
Glomerular filtration rate 0.97 0.15 0.83 0.11 0 0
mi/minlg
Substrate delivered
iO mol/min/g
to the luminal side 9.69 1.55 8.25 0.27 0 0
to the basolateral side 297.7 28.5 313.4 19.4 167.9 19.4 133.6 15.8
to the whole kidney 307.4 27.9 321.6 18.9 167.9 19.4 133.6 15.8
Time mm 0-5 0-10 0-5 0-10 0-5 0-5
DA excreted in the urine
1O mol/mmnlg 0.53 0.2l' 1.06 0.36 0.91 0.46 1.82 0.39 0 0
% versus substrate delivered 5.47 10.9 11.0 22.1 I I
to the luminal side
versus total DA release 27.7 41.1 13.8 25.2 0 0
DA release into the perfusate
JO9molImin/g 1.38 0.28 1.52 0.30 5.70 1.97a 5.41 1.76a 0.43 019b 24.7 62b
% versus substrate delivered 0.46 0.51 1.82 1.73 0.23 19.1
to the basolateral side
versus total DA release 72.3 58.9 86.2 74.8 100 100
Total DA release (urine and
perfusate)
1O mol/minlg 1.91 0.42 2.58 0.57 6.61 2.24a 7.23 2.04a 0.43 0.19c 24.7 6.2"
% versus substrate delivered 0.62 0.84 2.18 2.24 0.23 19.1
to the kidney
Gludopa and L-dopa were present initially in the perfusate at iO M. Kidneys were perfused in a closed circuit with 50 ml of perfusion medium.
Substrate delivered respectively to the whole kidney, to the luminal side and to the antiluminal side were calculated as specified in Methods.
Statistical analysis refers to comparisons of DA release induced by gludopa or L-dopa at similar times on filtering kidneys ( P < 0.05 one-tailed
test); to comparisons for gludopa or L-dopa of DA release on filtering and non-filtering kidneys (" P < 0.05; P < 0.02) and to comparisons of DA
release in urine or perfusate (" P < 0.05); Student's t-test on paired data. Data are presented as means saM; N 5 or 6.
perfusate had not changed after 90 minutes of perfusion (initial
inulin concentration: 0.41 0.005; final concentration: 0.40
0.007 glliter, N = 4) whereas it had fallen from 0.47 0.001 to
0.32 0.02 g/liter (N 11) over the same time-span in filtering
kidneys.
In the absence of glomerular filtration, the endorenal DA
synthesis could only be evaluated from the changes in the DA
release in the perfusate. Compared with the filtering kidneys,
after the injection of gludopa, the maximum DA concentration
in the perfusate was reduced by half (0.31 0.03 x 10—6 M
instead of 0.69 0.13) and the total DA release into the
perfusate always decreased, whatever the time considered
(Tables 1 and 2). An inverse figure was observed when L-dopa
was administered to non-filtering kidneys. The maximum DA
concentration in the perfusate increased considerably (3.72
0.69 x 10—6 M instead of 1.1 0.27, P < 0.02) and the DA
release into the perfusate was even two to three times higher
than the total DA release (perfusate and urine) in filtering
kidneys (Table 2).
Vascular effects of dopamine, L-dopa and gludopa
DA (10—v to i0 M) induced a concentration-dependent
relaxation in the renal vascular bed in which the tone had been
re-established by the perfusion of PGF2,, and in which the
alpha- and beta-adrenoceptors had been inhibited (Fig. 4A).
The maximum vasodilator response induced by DA, for a given
concentration, was reached in five minutes. Maximum relax-
ation was obtained with 4.4 x 1O or 1.4 X i0 M of DA, and
corresponded to 65.3 3.9% of the vasodilator response to
l0— M papaverine. EC50 was calculated as 3.1 0.6 x 106 M
(N = 5). The vasodilator response to DA was competitively
antagonized with SCH 23390 (3 x l0 M): the concentration-
response curve for DA was shifted rightwards, in parallel
fashion, by a factor of 15 (EC5O of 50 15 x 10—6 M, N = 4)
without the maximum vasodilatation induced by DA being
affected (61.1 7.5% relaxation for 4.4 x 10 M of DA).
Under similar experimental conditions, gludopa and L-dopa
also induced concentration-dependent renal vasodilatation (Fig.
4B, 4C) but this vascular effect only began at high concentra-
tions, 4 x 10—6 M for L-dopa and i0 M for gludopa. The
relaxation developed more slowly, taking 15 and 25 minutes,
respectively, to reach the maximum. Maximum vasodilatation
induced by L-dopa did not differ significantly from that induced
by DA (64.7 5.3% relaxation for 4.4 x iO M of L-dopa, N
8)buttheEC50forL-dopa(27.4 5.1 X 106M)was lOtimes
higher than that for DA (P < 0.001). Figure 5 shows an
experimental plot for the relaxations induced by gludopa be-
tween iO and 4 x iO M. For the latter concentration, mean
relaxation was 30.6 2.8% (N 6) of the response to
papaverine; the vasodilator response induced by iO M of DA
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Fig. 2. The cumulative DA release, on filtering kidneys, into the
perfusate (•), theurine (A), or the sum of both (U) andDA relase in the
perfusate on non-filtering kidneys ()after addition of L-dopa to the
perfusate. L-dopa was injected at the 35th mm of perfusion to give an
initial concentration of iO at in the perfusate. Aliquots of the renal
venous effluent were sampled every 5 or 10 mm, Urine was collected
over the same periods. Statistical significance refers to the comparison
of cumulative total DA release on filtering and non-filtering kidneys. *P
<0.05; < 0.01. Means sEM; N = 5 or 6.
on the same preparations was 73.9 3.1%. In view of the cost
of gludopa, we could not establish complete concentration-
response curves. In the presence of SCH 23390 (3 x iO M),
the relaxations induced by gludopa and L-dopa were inhibited.
Studies with AT-125 and carbidopa
In the presence of AT-125, the renal vasodilatation induced
by gludopa was significantly reduced (Fig. 4C). The inhibition
of endorenal DA synthesis was evaluated by measuring the DA
concentrations in the perfusate (Table 3). The DA concentra-
tions in the recirculating medium, measured when the vasodi-
lator effects reached a plateau, were lower in the presence of
AT-125 than after the injection of gludopa alone. Moreover,
these DA concentrations and the vasodilatations observed
perfectly matched those of the concentration-response curve of
DA itself (Fig. 4A).
We did not find any gamma-glutamyl dopamine synthesis in
the presence of AT-125.
In the presence of carbidopa, the renal vasodilatation induced
by L-dopa was also reduced (Fig. 4B). The endogenous renal
DA synthesis was inhibited since the DA concentration in the
perfusate was only 0.08 x l06 M after carbidopa, whereas it
reached 10—6 M in filtering kidneys in the absence of carbidopa
(Table 3). The vasodilatation measured for the DA concentra-
tions obtained in the perfusate, again corresponded perfectly to
the vasodilatation observed in the concentration-response
curve of DA itself.
The vasodilator response induced by DA itself was not
affected by the presence of AT- 125 or of carbidopa. DA induced
relaxations of 79.8 7.2% (N = 4) and 75.9 3.5% (N = 3),
respectively, versus 65.3 3.9% (N 5) when tested alone.
Discussion
The isolated kidney preparation enabled us to analyze the
endorenal metabolism of gludopa. DA is formed and appears
both in the urine and in the venous effluent. This metabolism is
not affected by the level of renal vascular resistance, whether
PGF2,, is being perfused or not. Our results show that gamma-
GT intervenes in the metabolism of gludopa, since treating the
preparation with its inhibitor, AT-l25 [23], inhibits DA synthe-
sis by 80%. We also confirm that gamma-GT is the first
enzymatic pathway in the synthesis of DA from gludopa, since
gamma-glutamyl dopamine did not accumulate in the presence
of AT- 125. This result agrees with the metabolic scheme
proposed by Worth et al [10] that gamma-GT intervenes before
AADC in the catabolism of gludopa.
Like Baines and Chan [26], Suzucki et al [27], Baines and
Drangova [28], Adam and Adams [29], Buu et al [30], we
confirm the endorenal synthesis of DA from L-dopa. DA
appears both in the urine and the perfusate. In our study, the
L-dopa metabolism into DA gave a greater yield than in the
study on isolated rat kidney by Suzuki et al [27}, who studied
the renal metabolism of L-dopa without inhibiting its catabo-
lism. Thus, under our experimental conditions, DA catabolism
can be considered to be accurately blocked. The AADC in-
volved in the metabolism of L-dopa is a cytosolic enzyme [31]
mainly present in the cells of the proximal tubules [15]. In these
cells, L-dopa is metabolized whether the cells are approach
from the basolateral or luminal side [26]. Our results show, in
the case of the non-filtering kidney, how important the synthe-
sis via a basolateral approach can be. DA release in the
recirculating medium is then considerably higher. This is ac-
counted for by the single-line release of the DA synthesized in
the cytosol of the tubular cells, towards the circulation because
the intratubular pressure is raised by the ureter's being ligated.
On the other hand, high urinary DA clearance on filtering
kidneys allows the DA accumulation in the perfusate to remain
low. Curiously enough, total DA release after L-dopa injection
was higher with non-filtering kidneys than with filtering ones.
The high intratubular pressure following the ureter ligature may
favour DA release from the cytosol.
On the isolated rat kidney, the metabolism of gludopa differs
in two respects from that of L-dopa: it occurs globally with a
lower yield, and gludopa is metabolized to a greater extent via
a luminal approach to the enzymatic system. Indeed, the DA in
the perfusate or in the urine and the total DA release were all
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Table 2. Cumulative total DA release (perfusate and urine) in filtering and non-filtering, isolated perfused rat kidneys
Substrate
Filtering kidneys
Gludopa L-dopa
Substrate present in the 586.9 25.9 602.3 15.2
perfusate
io- molig kidney wt
Time mm 5 30 50 5 30
Cumulative total DA release
iO mollg kidney wt 9.54 2.10 73.7 15.8 86.7 19.2 33.1 l1.2a 131.2 31.9
versus substrate initially 1.63 12.6 14.8 5.5 21.8
present in the perfusate
Non-filtering kidneys
Substrate present in the 609.0 14.1 585.9 9.8
perfusate
1O molig kidney wt
Time mm 5 30 50 5 30
Cumulative total DA release
1O molig kidney wt 2.15 O.93 12.5 1.4C 13.8 2.6c 123.4 3l.l' 167.8 35.0
% versus substrate initially 0.35 0.05 2.27 21.1 28.6
present in the perfusate
Cumulative total DA release was analyzed during various durations of perfusion (5, 30 or 50 mm) after substrate (gludopa or L-dopa) injection
to the recirculating medium. The substrate present initially in the perfusate was calculated from the initial concentration of substrate (10—i M) x
50 ml of perfusion medium, corrected for the kidney weight.
Statistical analysis refers to comparisons between DA release induced by gludopa or L-dopa at similar times on filtering kidneys (C P < 0.05,
one-tailed test) or to comparisons of DA release on filtering and non-filtering kidneys for gludopa or L-dopa (b P < 0.05; C P < 0.01), Data are
presented as mean sEM; N = 5 or 6.
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Fig. 3. Renal clearance for dopamine (mi/mm g ofkidney wt) after
the addition of L-dopa (U, N 5) or gludopa (•, N = 5) to the
perfusate of isolated perfused rat kidneys. Drugs were administered at
the 35th mm of perfusion to give an initial perfusate concentration of
1O M. Means SEM.
lower after gludopa than after L-dopa, although both precursors
were initially present at the same concentration in the perfu-
sate. This difference is probably linked to the fact that gludopa
metabolism requires access to two enzymes, but a difference in
the endorenal accumulation of DA cannot be ruled out. The
importance of the gludopa metabolism via a luminal approach
stems from our results on non-filtering kidneys. The DA con-
centration in the perfusate and the total DA release into the
recirculating medium remain extremely low there, although the
urinary clearance of DA is abolished. This result cannot be
accounted for by the difference in the perfusion flow rate
between filtering and non-filtering kidneys since the gludopa
concentration in the perfusate remains the same and since the
decrease in the perfusion flow rate was not a limiting factor in
the metabolism of L-dopa.
Gamma-GT is a membraneous glycoprotein of the proximal
tubule [321 which is present on the brush border of rat tubular
epithelial cells [33, 34]. Gamma-GT has also been localized on
the basolateral side of the same cells by immunocytochemistry
[14]. Its activity has sometimes, but not always, been found on
isolated basolateral membranes [35, 36]. Since antiluminal
gamma-GT activity has clearly been demonstrated on isolated
non-filtering rat kidneys [37, 38], a vascular localization of the
enzyme may also be considered. Arguments for that localiza-
tion have been based on glomeruli and renal microvessels [37,
391. Gamma-GT-specific activities in the renal microvascular
compartment and on basolateral membranes (0.25 to 1 U/mg
protein) [35, 39] are very low compared to those on brush
border membranes (25 U/mg protein) [40]. However, since the
delivery of substrate to the antiluminal side of tubular cells is
higher than to the luminal side, the rate of product release in the
circulation becomes higher than the excretion rate in the urine
E
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Table 3. Concentration of DA in the perfusate after gludopa and L-dopa administration
Gludopa concentration
in the perfusate
Gludopa (10 M)
3 13 43
Control (N = 6) 0.02 0.01 0.45 0.07 2.52 0.48
AT-125 (N = 4) ND 0.09 0.ola 0.46 0.o7
L-dopa concentration
in the perfusate
L-Dopa (l06 M)
10 40 140 440
Control (N = 5) 1.03 0.21 ND ND ND
Carbidopa (N = 3) 0.08 0.04a 0.12 0.04 0.42 0.15 1,57 0.10
ND = not determined. DA release into the perfusate were measured either when the substrates (gludopa or L-dopa) were administered alone
or in the presence of AT-125 or carbidopa. AT-125 was added directly to the perfusate (10-6 M); carbidopa (5 mg/kg, i.p.) was injected to rats 30
mm before the kidney was set on perfusion and was also added to the perfusate (10—a M).
Statistical significance refers to the comparison of DA concentrations in the presence and in the absence of AT- 125 or carbidopa, a P < 0.01.
Data are presented as means SEM.
[23]. Our results with gludopa-induced DA release into the
vascular or urinary compartments tally with the data from Dass
and Welbourne [23], at least during the first five minutes after
gludopa injection. After longer recirculation, the cumulative
amounts of DA in the perfusate and in the urine become equal
(after gludopa and also L-dopa injections), probably reflecting
the high catecholamine clearance attributed to glomerular fil-
tration and proximal tubular secretion.
Globally, gludopa metabolism by the isolated kidney is less
reactive than gamma-glutamyl-p-nitroanilide, another substrate
for gamma-GT generating p-nitroanilide [38]. This difference
may be attributed to three facts: 1) in our experiment, a second
enzymatic step (AADC) intervenes which has its own limits, as
shown by our study with L-dopa; 2) we do not add [38] a
gamma-glutamyl acceptor to our medium, that is, glycylglycine,
but supplement the perfusate with the natural aminoacid L-
glutamate; this aminoacid is also a gamma-glutamyl acceptor
but less potent than glycylglycine in increasing the Vm and
decreasing the Km of gamma-GT [41]; 3) the gludopa concen-
tration used in our study was relatively low compared to its Km
[121 and gamma-GT therefore probably did not work at its
M optimum.
In non-filtering kidneys, the amount of DA released into the
perfusate and its concentration therein are halved after 30
minutes of recirculation. Such a limited decrease (and not a
suppression) of perfusate DA would not be sufficient to com-
pletely abolish the renal effects of gludopa. We therefore
suggest that, in pathological situations where the glomerular
filtration rate is reduced, gludopa should be given at higher
doses if dopaminergic effects on the kidney are expected.
i0 M The renal vasodilatation induced by L-dopa and gludopa is
clearly linked to the stimulation of DA- 1 receptors since it is
inhibited by SCH 23390, a selective antagonist of these recep-
tors [22, 42]. Since the vascular effects of L-dopa and gludopa
are inhibited respectively by an AADC inhibitor or a gamma-
GT inhibitor, these dopamine prodrugs have no vascular effects
per se. Our results thus show that endorenal DA synthesis can
induce renal vasodilatation similar to that previously reported
after exogenous DA administration [42]. The vascular re-
sponses were the same whether DA itself was injected or the
DA concentration in the perfusate was raised following gludopa
or L-dopa injection. This implies that the DA synthesized by
the proximal tubule cells passes into the circulation and stimu-
lates the vascular DA- 1 receptors.
Our results tally with the data obtained with gludopa by Lee
and his colleagues: in healthy volunteers, gludopa increased the
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Fig. 4. Relaxation induced in the presence ofphenoxybenzamine (1O—
M) and sotalol (1O M) by dopamine (A), L-dopa (B) and gludopa (C) in
the isolated perfused rat kidney. Drugs were tested after vascular tone
had been re-established by continuous PGF2a perfusion (1.2 x l0_8
mol/min). Relaxation is expressed as the percent reduction in the
increase in renal perfusion pressure induced by PGF2a. Results are
given as means SEM. Numbers in brackets refer to the number of
experiments. Statistical significance refers to the comparison for each
drug with the control response curve. *P < 0.05; **P < 0.01; <
0.001.
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renal blood flow, and this effect was not inhibited by domperi-
done, a DA-2 receptor antagonist, but was antagonized by
(+)sulpiride, a preferential DA-1 receptor antagonist [10, 43,
44]. In those studies, the DA synthesized from gludopa was
found to reduce the plasma renin activity by stimulating the
renal nerve endings presynaptic DA-2 receptors [43]. Thus,
dopamine release confined to the renal parenchyma, leading to
simultaneous stimulation of the DA-1 and DA-2 receptors,
might prove more advantageous than the systemic administra-
tion of an agonist specific for the DA- 1 receptors.
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